We provide information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.
Type
Public
HQ
Worthing, GB
Founded
1934
Size (employees)
506 (est)+15%
Allergy Therapeutics was founded in 1934 and is headquartered in Worthing, GB
Report incorrect company information

Allergy Therapeutics Office Locations

Allergy Therapeutics has an office in Worthing
Worthing, GB (HQ)
Dominion Way
Show all (1)
Report incorrect company information

Allergy Therapeutics Financials and Metrics

Allergy Therapeutics Financials

Allergy Therapeutics's revenue was reported to be £64.14 m in FY, 2017
GBP

Revenue (FY, 2017)

64.1 m

Gross profit (FY, 2017)

47.4 m

Gross profit margin (FY, 2017), %

73.9%

Net income (FY, 2017)

(2.5 m)

EBITDA (FY, 2017)

109 k

EBIT (FY, 2017)

(1.9 m)

Market capitalization (31-Oct-2017)

202 m

Closing share price (31-Oct-2017)

0.3

Cash (30-Jun-2017)

22.1 m

EV

181.8 m
Allergy Therapeutics's current market capitalization is £202 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

25.7 m31 m37.8 m40.8 m41.6 m41.3 m39.3 m42 m43.2 m48.5 m64.1 m

Revenue growth, %

7%3%12%

Cost of goods sold

10.1 m10.9 m13.6 m11.2 m13.2 m13.7 m12 m12 m12.2 m14.1 m16.8 m

Gross profit

15.7 m20.2 m24.2 m29.6 m28.3 m27.6 m27.3 m30 m31.1 m34.4 m47.4 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(23.8 m)(20.3 m)(11.8 m)586 k(2.7 m)823 k633 k741 k108 k(13.1 m)(2.5 m)

Cash From Operating Activities

20.3 m19.3 m(440 k)1.7 m(2 m)2.9 m2.4 m2.2 m3.1 m(11.8 m)178 k

Cash From Financing Activities

2.7 m18.6 m103 k4.9 m764 k(2.7 m)148 k20.1 m12.5 m(188 k)

Net Change in Cash

17.7 m3.4 m(2.3 m)4.6 m(3.6 m)(1.4 m)1.4 m1 m20.5 m(792 k)(2 m)
GBPY, 2017

EV/EBITDA

1.7 k x

EV/EBIT

-95.9 x

EV/CFO

1 k x

Revenue/Employee

135.6 k

Debt/Equity

0.1 x

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information